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Response to cancer immunotherapies depends on the complex and dynamic interactions 
between T cell recognition and killing of tumor cells that are counteracted through 
immunosuppressive pathways in the tumor microenvironment. Therefore, while measurements 
such as tumor mutational burden provide biomarkers to select patients for immunotherapy, they 
neither universally predict patient post-treatment outcome nor imply the mechanisms that 
underlie immunotherapy resistance. Recent advances in single cell RNA sequencing technology 
(scRNA-seq) measure cellular heterogeneity within cells of an individual tumor but have yet to 
realize the promise of predictive oncology. In addition to data, mechanistic multiscale 
computational models are being developed for predicting cellular states during tumor 
progression and treatment response. Incorporating single cell data from a tumor to parameterize 
these computational models can lead to a deeper insight into subsequent tumor progression and 
predictions of clinical outcome in an individual. While the high dimensionality of single cell 
analysis data poses a challenge for integration, Quantitative System Pharmacology (QSP) models 
incorporate discrete cellular states that can be obtained directly from single cell data. Here, we 
integrate whole exome sequencing and scRNA-seq data from Triple Negative Breast Cancer 
(TNBC) patients to model neoantigen burden in tumor cells as input to a spatial Quantitative 
System Pharmacology (spQSP) model that comprises four compartments (tumor, tumor-draining 
lymph node, central and peripheral) to represent a whole patient and uses spatial agent-based 
model (ABM) to represent tumor volumes at the cellular scale. We use the high-throughput 
single-cell data to model the role of antigen burden and heterogeneity relative to the tumor 
microenvironment composition on predicted immunotherapy response. Using this model, we 
found that patients with more tumor neoantigens have better responses to immunotherapy. In 
iii 
 
addition, patients with more heterogeneous neoantigen profile in cancer cells are predicted with 
worse treatment outcomes. This thesis demonstrates the feasibility of merging high throughput 
data to initialize cell states in multiscale computational models such as the spQSP for 
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Breast cancer is the most frequently diagnosed and leading cause of cancer death among 
female population in the world (Bray et al., 2018). Triple Negative Breast Cancer (TNBC), 
which is defined as the type of breast cancer characterized by absence of expression of estrogen 
receptor (ER), progesterone receptor (PR) and Erb-B2 receptor tyrosine-protein kinase (HER2), 
has the poorest treatment outcome among all breast cancer subtypes due to lack of therapeutic 
molecular targets. Whereas other hormone receptor positive subtypes of breast cancer benefit 
from targeted therapies, the absence of receptor expression does not allow for such precision 
therapeutic selection in this cancer type. Immunotherapies that reinvigorate the host’s immune 
system to eradicate cancer cells have emerged as promising alternatives to chemotherapy and 
targeted therapy(Benvenuto et al., 2019). To that end, immune-checkpoint inhibitor (ICI) therapy 
or immunotherapy including nivolumab, pembrolizumab (anti‑PD1), atezolizumab, durvalumab 
(anti-PDL1), ipilimumab, tremelimumab (anti-CTLA4) were studied in multiple clinical trials 
among TNBC patients to investigate efficacy of immunotherapy in either monotherapy or 
combination therapy (Bianchini et al., 2016). The Objective Response Rate (ORR) ranges from 
4.8% to 62% for all recent TNBC clinical trials involving different types of ICIs (Emens, 2021; 
Malhotra & Emens, 2020; Planes-Laine et al., 2019). The wide range of ORR suggests the need 
for effective, mechanistic biomarkers to predict treatment outcome for individual patients. All 







Agent-based model ABM 
Antigen Presenting Cell APC 
Arginase-1 Arg-I 
Chemokine (C-C motif) ligand 2 CCL2 
Cancer stem-like cell CSC 
Cytotoxic T lymphocytes  CTL 
Cytotoxic T-lymphocyte-associated protein 4 CTLA-4 
Immune Checkpoint Inhibitor ICI 
Interferon gamma IFNγ 
Interleukin 2 IL-2 
Latin Hypercube Sampling LHS 
Myeloid Derived Suppressor Cell MDSC 
Nitric Oxide NO 
Ordinary Differential Equation ODE 
Programmed cell death protein 1  PD-1 
Partial Differential Equation PDE 
Programmed death-ligand 1 (2) PD-L1 (2) 
Quantitative System Pharmacology QSP 
Region of Interest ROI 
Single cell RNA sequencing scRNA-seq 
Tumor Mutational Burden TMB 
Tumor Microenvironment TME 
Tumor Specific Neoantigen TSA 
Table 1: Table of abbreviations used in this thesis. 
The interplay between the immune cells and malignant cells within the tumor ultimately 
drive successful response to ICI. Within the tumor cells, tumor mutational burden (TMB), 
defined as total number of somatic mutations per megabase in tumor genome, has been 
recognized as a biomarker to predict effectiveness of immunotherapy in multiple clinical trials 
(Brown et al., 2014; Fumet et al., 2020). The greater number of mutations reflected in higher 
TMB correlates with a higher probability of neoantigens, which can be recognized by T cells to 
elicit immune response (Jiang et al., 2019). However, other studies have shown high TMB 
cannot guarantee patients’ responses to immunotherapy due to either insufficient immune cell 
infiltration or therapeutic resistance resulting from tumor cell heterogeneity (Kazdal et al., 2019; 
Maleki Vareki, 2018). Tumor heterogeneity has three major sources: genetic, phenotypic, and 
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microenvironmental.  Intratumoral heterogeneity leads to acquired resistance during treatments, 
and intertumoral heterogeneity leads to different patients response to the same treatment 
(Marusyk et al., 2020). Experimental studies have further demonstrated that high expression of 
diverse neoantigens can lead to reduced immune attack over systems with similar expression of a 
homogeneous population of neoantigens(Gejman et al., 2018). Thus, predicting individual 
outcomes to ICI could be enhanced by extending from population-level biomarkers to modeling 
the impact of this tumor and immune cell heterogeneity within individual tumors. 
Advanced omics technologies spanning DNA, RNA, and proteomic scales have enabled 
researchers to gain deeper insight of tumor heterogeneity at individual patient’s level. Many 
groups characterize immune cell landscape through single cell RNA sequencing data (scRNA-
seq) for various types of cancer (Azizi et al., 2018; Guo et al., 2018; L. Ma et al., 2019; Zhang et 
al., 2019; Zheng et al., 2017). These technologies can be used both to determine immune cell 
composition in the tumor microenvironment (TME) along with the molecular states of tumor 
cells(Lim et al., 2020). These technologies have been widely applied to study the state of breast 
tumors(Azizi et al., 2018). Likewise resolved molecular profiling technologies provide further 
opportunities to characterize the tumor microenvironment(Jackson et al., 2020; Keren et al., 
2018), but are only just emerging at high-dimensional molecular resolution to characterize the 
pathways in both tumor and immune cells(Andersson et al., 2020; He et al., 2020). 
Characterizing the heterogeneous molecular and cellular states with greater resolution helps not 
only to identify novel biomarkers, but also to understand the significance of these pathways and 
inter-cellular interactions in ICI response.  
At the same time as high-throughput tumor atlases are emerging, mechanistic 
computational models are also developing as powerful tools to predict patients’ responses to 
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cancer immunotherapy(Rozenblatt-Rosen et al., 2020). For instance, Quantitative System 
Pharmacology (QSP) models that simulate biological processes, pharmacokinetics (PK), and 
pharmacodynamics (PD) of selected drugs, have becomes an indispensable tool for drug 
discovery and designing dosing regimen (Bai et al., 2019; Helmlinger et al., 2019; Sové et al., 
2020). QSP models are often validated by results of clinical trials to reflect their predictive 
power (Jafarnejad et al., 2019; H. Ma et al., 2020; Wang et al., 2020, 2021). Despite QSP 
models’ ability to reasonably reproduce clinical outcome at population level, due to their 
compartmental nature and their lumped representation of tumor the models are unable to 
characterize cellular or spatial heterogeneity for individual patients. To address that issue, Gong 
et al. developed a multiscale agent-based model (ABM) to simulate spatio-temporal tumor 
progression and simulation results can be visualized with single cell resolution (Gong et al., 
2017). Further integrating omics data into QSP models can parameterize these models for 
individual patients, providing the prospect to simulate a virtual patients’ longitudinal response to 
various therapeutic regimens. Lazarou et al. proposed integrating omics data into QSP models at 
multiscale levels (tissue, cellular, and molecular) (Lazarou et al., 2020). Johnson et al. integrated 
single cell RNA sequencing data with mechanistic model to improve predictive accuracy of 
chemotherapy responses (Johnson et al., 2020). The robust characterization of cellular 
heterogeneity by single cell technologies makes them ideally suited for integration with QSP 
models predicting ICI response. 
 In this study, we extend our spatial Quantitative System Pharmacology (spQSP) model to 
integrate single-cell RNA-sequencing data. We incorporate single cell sequencing data and 
whole exome sequencing data of triple negative breast cancer tumors from Chung et al. into a 
spQSP model(Chung et al., 2017) to enable patient-specific models. We leverage this model to 
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predict the impact of tumor neoantigen profiles and neoantigen heterogeneity on response to 
immunotherapy. Altogether, this integrated system provides a new framework to combine omics 
data of tumor cell heterogeneity with computational QSP model to model ICI response.  
 
2. Methods 
2.1 spQSP Platform Formulation 
 The spQSP model consists of two modules: a whole-patient QSP model and a tumor 
compartment-specific agent-based model (ABM). The QSP model is expressed in terms of 
ordinary differential equations (ODE) and algebraic equations that simulate tumor progression 
dynamics at organ level (Sové et al., 2020; Wang et al., 2020, 2021). The ABM, representing a 
1𝑚𝑚𝑚𝑚 × 1𝑚𝑚𝑚𝑚 × 1𝑚𝑚𝑚𝑚 region of interest in the tumor, that simulates spatio-temporal molecular 
and cellular interactions in three-dimensional space(Gong et al., 2017). Specifically, we modified 
the original framework to include the further effect of myeloid derived suppressor cells 
(MDSCs) and T cell recognition of antigens to better tailor this model to breast cancer. A 
schematic of the spQSP model comprising a whole-patient compartmental ordinary differential 
equation-based QSP model and a spatial agent-based model (ABM) representing a region-of-







Figure 1: Schematic of the spQSP model, which is comprised of a QSP module and an ABM module. Left: The four-
compartments QSP model is presented, including tumor, central blood, lymph node, and peripheral, which 
simulates the process of T cell priming, Immune cell trafficking, immune-cancer interactions, antigen collection and 
presentation. Right: ABM module partially represents the tumor compartment, which further model immune-tumor 
interactions spatial-temporally.  
2.1.1 QSP module 
The QSP model is comprised of four major compartments: Tumor compartment, where 
cancer cells proliferate and anti-tumoral activities take place; Lymph node, where naïve CD8+ T 
cell priming initiates with tumor neoantigen on antigen presenting cells (APCs) followed by T 
cell expansion; Central compartment represents blood in human body, transporting endogenous 
molecules, cells and drugs to different parts of the body; Peripheral compartment represents 
other organs in the body.  
2.1.2 Agent rules in ABM 
Current version of spQSP model is an extension of our previous immuno-oncology ABM 
model(Gong et al., 2017). Here we significantly extended the model by introducing additional 
cell types, detailed rules governing agents’ interactions, and explicitly considered heterogeneous 
tumor neoantigens on cancer cells. In general, the ABM module has two distinct types of agents: 
cellular agents and molecular agents. There are four major cell types: cancer cells, CD8+ T cells, 
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FoxP3 regulatory T cells, and myeloid- derived suppressor cells (MDSCs). In turn, cancer cells 
are subdivided into cancer stem-like cells (CSCs), cancer progenitor cells, and cancer senescent 
cells; CD8+ cytotoxic T lymphocytes (CTLs) are subdivided into effector, cytotoxic, and 
exhausted T cell. Cellular agents and cell-cell interactions are governed by defined rules as 
explained in the following sections. The concentration of molecular agents, mainly cytokines, is 
described by Partial Differential Equations (PDEs) that are solved numerically. Soluble factors 
considered include cytokines CCL2, IL-2, IFNγ, enzyme Arg-I, and a signaling molecule NO. 
All immune-cancer interaction rules are based on published oncology literature; details can be 
found in recent reviews (Groth et al., 2019; Topalian et al., 2020).  
2.1.3 ABM environment 
Due to computational limitations, it is not feasible or necessary to track all cells within a 
tumor beyond a certain size (e.g. > 1011 cells). Therefore, we only simulate tumor dynamics 
within one or several regions of interest (ROI) that can be placed at any tumor locations, e.g. at 
the invasive front or tumor core. The goal of the present study is to demonstrate the feasibility 
and general features of the spQSP platform, especially the incorporation of omics data; thus, we 
did not make an effort to expand the size of the ROI to the limits of available computing power. 
In this study, we choose 1 × 1 × 1 mm3 as our ROI, but the volume can vary based on 
computational power and can be increased several folds. Assuming the diameter of cancer cell is 
20 microns, we set the volume of each voxel to be 20x20x20 microns in our simulated volume. 
Therefore, our ROI contains 50x50x50 voxels. Since each voxel holds one cancer cell, the 
maximum number of cancer cells in the simulated volume is 125,000. We allow eight (one) T 
cells to exist in the same voxel without (with) the cancer cell presence. All cells can only move 
to the six directly adjacent voxels (also known as von Neumann neighborhood), whereas cells 
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can interact with cells in the Moore neighborhood (26 surrounding voxels)(Gong et al., 2017). 
To represent tumor vasculature, the entry points of recruited T cell are randomly allocated in the 
ROI when the model is initialized. The abundance of entry points can be varied by changing 
vascular density in the model. The tumor vascular density is determined from the experimental 
data (Stamatelos et al., 2014, 2019) . 
Cancer cell 
The cancer cell differentiation mechanism is adopted from Norton et al.(Norton et al., 
2018). Each cancer cell has three states: cancer stem-like cell (CSC), progenitor cell, and 
senescent cell. CSCs can either symmetrically divide into two daughter CSCs or asymmetrically 
divide into one CSC and one progenitor cell with a defined probability. CSCs have unlimited 
rounds of division. Progenitor cells have limited rounds of division before turning into senescent 
cells, and their daughter cells are only progenitor cells. Senescent cells cannot divide and will 
eventually die with defined death rate. All cancer cell related parameters (reproduction rate, 
death rate, etc.) are defined in the QSP module. 
CD8+ T cell 
CD8+ T cells has three distinct states in this model: effector, cytotoxic, and exhausted. 
All CD8+ T cells recruited from the central compartment are effector T cell. Effector T cells are 
further activated to cytotoxic state upon encountering cancer cells. Cytotoxic T cell can release 
IFNγ and IL-2 to the surrounding spaces. IFNγ induces PD-L1 expression on all cells. The PD-
L1 expression on a specific cell is determined by its surrounding IFNγ concentration, the 
relationship governed by a Hill function. IL-2 promotes CD8+ T cell expansion in the tumor. If 
cytotoxic T cells are exposed to sufficient concentration of IL-2, they start limited cycles of 
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divisions. CD8+ T cells can be exhausted by surrounding PD-L1 since all CD8+ T cells are 
assumed to express PD-1. Adjacent FoxP3+ regulatory T cells (Treg) can also exhaust CD8+ T 
cells which can no longer kill cancer cells and die with defined rate. 
FoxP3+ regulatory T cell (Treg) 
Treg recruitment mechanism is identical to CD8+ T cell and they share the same entry 
points. Treg cells can exhaust CD8+ T cells. Both exhaustion rate and Treg death rate are 
determined by parameters in the QSP model. 
MDSC 
MDSC recruitment mechanism resembles that of other immune cells. MDSCs secrete 
chemokine (C-C motif) ligand 2 (CCL2), Nitric Oxide (NO), and Arginase 1 (Arg-I). CCL2 
facilitates recruiting MDSC; NO reduces CD8+ T cell killing capacity; and Arg-I promotes Treg 
reproduction. Secretion rate, diffusion rate, and degradation rate for all cytokines are determined 
by experimental data and provided in the supplemental parameter files(Dutta et al., 2018; Francis 
& Palsson, 1997; Hakim et al., 1996; B. Huang et al., 2007; Y. Ma et al., 2005; Schimke, 1964; 
Schweighofer & Ferriol, 2000; Serafini et al., 2008; Tanimoto et al., 2008). 
 
2.1.4 QSP-ABM coupling 
The spQSP model extends the QSP model by adding a spatially resolved, fine-grained 
ABM model; henceforth the QSP and ABM are sometimes referred to as modules to reflect that 
they are parts of the integrated spQSP model. The high granularity of ABM model where 
discrete cancer and immune cells of different type are spatially resolved and whose temporal 
behavior is followed, creates heterogeneous tumor microenvironment that resembles tumor in 
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patients. However, single cell RNA sequencing data we use in this study have no spatial 
resolution, thus we randomly initialize cancer cells at the bottom corner of the simulated volume. 
Both QSP and ABM modules are written in C++ language. To couple QSP module with ABM, 
the following procedure was taken. We converted the QSP module reported in system biology 
markup language (SBML) in Wang et al. with a few modifications mentioned above to C++ 
classes(Wang et al., 2020). Then the ODE system of the QSP module is solved using SUNDIAL 
CVODE package(Cohen & Hindmarsh, 1996). Since the ABM module represents a portion of 
the tumor in the QSP module, we use equations and parameters in the QSP module to determine 
the mechanisms in the ABM module. Finally, the shared information between the ABM and QSP 
modules is handled by scaling variables in the QSP module. 
In the QSP module, cancer cells have only one state, and the dynamics is governed by 
one growth term and multiple death terms, including immune cell killing rate and natural death 
rate. In contrast, in the ABM module, the cancer cells are differentiated into cancer stem-like 
cells, progenitor cells, and senescent cells, and rules are adapted from our previous models(Gong 
et al., 2017; Norton et al., 2018). Cancer stem-like cells have unlimited number of division 
cycles with a rate rs. The probability of asymmetric division is k, generating one daughter 
progenitor cell and one daughter stem-like cell. The probability of symmetric division is 1-k, 
generating two daughter stem-like cells. Progenitor cells, with limited number of divisions 
(dmax), divide at a rate rp. The parent cells become senescent after dmax cycles of division. 
Senescent cells cannot proliferate and have a fractional death rate of µ. To connect QSP and 
ABM cancer growth, we built an ODE version of the ABM rules for cancer cell growth 
dynamics for comparison purpose. Here Sc, Pi and Sn denote cancer stem-like cell, progenitor cell 






=  𝑟𝑟𝑠𝑠(1 − 𝑘𝑘)𝑆𝑆𝑐𝑐                (Eq. 1) 
𝑑𝑑𝑃𝑃1
𝑑𝑑𝑑𝑑
=  𝑟𝑟𝑠𝑠𝑘𝑘𝑆𝑆𝑐𝑐 −  𝑟𝑟𝑝𝑝𝑃𝑃1           (Eq. 2) 
𝑑𝑑𝑃𝑃𝑖𝑖
𝑑𝑑𝑑𝑑
= 2𝑟𝑟𝑝𝑝𝑃𝑃𝑖𝑖−1 − 𝑟𝑟𝑝𝑝𝑃𝑃𝑖𝑖     𝑓𝑓𝑓𝑓𝑟𝑟 2 ≤ 𝑖𝑖 ≤ 𝑑𝑑𝑚𝑚𝑑𝑑𝑑𝑑    (Eq. 3) 
𝑑𝑑𝑆𝑆𝑛𝑛
𝑑𝑑𝑑𝑑
= 2𝑟𝑟𝑝𝑝𝑃𝑃𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 − 𝜇𝜇𝑆𝑆𝑛𝑛        (Eq. 4) 
 
Combining equations (1) and (2): 
𝑑𝑑
𝑑𝑑𝑑𝑑





𝑟𝑟𝑠𝑠(1 − 𝑘𝑘) + 𝑟𝑟𝑝𝑝
 
As tumor volume increases, (𝑝𝑝𝑆𝑆𝑐𝑐 − 𝑃𝑃1) approaches 0. The same relationship is applicable 
to other cancer cell types, and the system asymptotically approaches a stable state where all 
cancer species grow with same rate r*. The ratio between each pair of cancer cell species 
asymptomatically approaches the constant r*: 
 




















= 𝑙𝑙2                              (Eq. 8) 
 
As all cancer cell species’ growth rates approach constant r*, the growth rate equals 
cancer cell growth rate from QSP module, which is defined in the QSP parameter file. Since r* 




, and 𝑟𝑟𝑝𝑝 and µ can be set independently. 
Based on results from Eq. 6-8, at steady state, the ratio between any pair of cancer cell species 
stays the same as tumor is expanding. We then calculate the fraction of each cancer cell species 











Table 2: At steady state, fraction of cancer cells grouped by cancer cell type. 𝑆𝑆𝑐𝑐: Stem-like cancer cell; 𝑃𝑃𝑖𝑖: 
Progenitor cancer cell at 𝑖𝑖𝑑𝑑ℎ division cycle. 𝑆𝑆𝑛𝑛: Senescent cancer cell 




Modifier function of PD-1–PD-LY interaction (Y=1 or 2) 
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We assume all CD8+ T cell express PD-1 and all cancer cells express PD-L1; this 
assumption can be readily changed to fit experimental data where available. Our model 
represents PD-L1 and PD-1 interactions in multiple ways. The model takes the number of PD-




1 + ( 𝑋𝑋𝐾𝐾_𝐶𝐶1_𝑃𝑃𝑃𝑃𝑃𝑃𝑃𝑃_𝑇𝑇𝑇𝑇𝑓𝑓𝑓𝑓_𝑃𝑃𝑃𝑃1)
𝑛𝑛
            (Eq. 9) 
where Y = 1,2 and 𝑋𝑋 = 𝐶𝐶_𝑃𝑃𝑃𝑃𝑃𝑃1_𝑇𝑇𝑇𝑇𝑓𝑓𝑓𝑓_𝑃𝑃𝑃𝑃1 + 𝐶𝐶_𝑃𝑃𝑃𝑃𝑃𝑃2_𝑇𝑇𝑇𝑇𝑓𝑓𝑓𝑓_𝑃𝑃𝑃𝑃1 , which is the total number 
of PD-1 – PD-LY bonds between CD8+ T cell and cancer cell (Tum denotes tumor). 
The number of PD-1 molecules in the immune synapse can be calculated as: 
𝑃𝑃𝑃𝑃1_𝑠𝑠𝑠𝑠𝑛𝑛_𝑑𝑑𝑓𝑓𝑙𝑙 = 𝑇𝑇𝑇𝑇𝑓𝑓𝑓𝑓_𝑃𝑃𝑃𝑃1_𝑑𝑑𝑓𝑓𝑑𝑑𝑑𝑑𝑙𝑙 ∙ 𝐴𝐴_𝑠𝑠𝑠𝑠𝑛𝑛/𝐴𝐴_𝑇𝑇  (Eq. 10) 
 
Total number of PD-L1 molecules involved in the immune synapse can be calculated as: 
𝑃𝑃𝑃𝑃𝑃𝑃1_𝑠𝑠𝑠𝑠𝑛𝑛_𝑑𝑑𝑓𝑓𝑑𝑑_𝑚𝑚𝑑𝑑𝑑𝑑 =  𝐶𝐶_𝑃𝑃𝑃𝑃𝑃𝑃1_𝑑𝑑𝑓𝑓𝑑𝑑 ∙ 𝐴𝐴_𝑠𝑠𝑠𝑠𝑛𝑛/𝐴𝐴_𝐶𝐶 𝑃𝑃𝑃𝑃𝑃𝑃1_𝑠𝑠𝑠𝑠𝑛𝑛_𝑑𝑑𝑓𝑓𝑑𝑑 
𝑃𝑃𝑃𝑃𝑃𝑃1_𝑠𝑠𝑠𝑠𝑛𝑛_𝑑𝑑𝑓𝑓𝑑𝑑 =  𝑃𝑃𝑃𝑃𝑃𝑃1_𝑠𝑠𝑠𝑠𝑛𝑛_𝑑𝑑𝑓𝑓𝑑𝑑_𝑚𝑚𝑑𝑑𝑑𝑑 ∙ 𝐻𝐻      (Eq. 11) 
Here, H is the Hill function for PD-L1 binding. 
In the current version of the ABM, expression of PD-L2 is not accounted for; thus, for 
consistency we also ignore PD-L2 in the QSP model. This and other simplifying assumptions 
can be relaxed in subsequent versions of the model. Assuming immune synapse reaches 
equilibrium 
𝑃𝑃𝑃𝑃1_𝑃𝑃𝑃𝑃𝑃𝑃1 =  𝑃𝑃𝑃𝑃1_𝑠𝑠𝑠𝑠𝑛𝑛 ∙ 𝑃𝑃𝑃𝑃𝑃𝑃1_𝑠𝑠𝑠𝑠𝑛𝑛 ∙ 𝑘𝑘1  
𝑃𝑃𝑃𝑃1_𝑁𝑁𝑖𝑖𝑁𝑁𝑓𝑓_𝑠𝑠𝑠𝑠𝑛𝑛 =  𝑃𝑃𝑃𝑃1_𝑠𝑠𝑠𝑠𝑛𝑛 ∗ 𝑁𝑁𝑖𝑖𝑁𝑁𝑓𝑓 ∙ 𝑘𝑘2  
𝑃𝑃𝑃𝑃1_𝑁𝑁𝑖𝑖𝑁𝑁𝑓𝑓_𝑃𝑃𝑃𝑃1_𝑠𝑠𝑠𝑠𝑛𝑛 =  𝑃𝑃𝑃𝑃1_𝑁𝑁𝑖𝑖𝑁𝑁𝑓𝑓_𝑠𝑠𝑠𝑠𝑛𝑛 ∙ 𝑃𝑃𝑃𝑃1_𝑠𝑠𝑠𝑠𝑛𝑛 ∙ 𝑘𝑘3  
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𝑃𝑃𝑃𝑃1_𝑃𝑃𝑃𝑃𝑃𝑃1 + 𝑃𝑃𝑃𝑃1_𝑠𝑠𝑠𝑠𝑛𝑛 + 𝑃𝑃𝑃𝑃1_(𝑁𝑁𝑖𝑖𝑁𝑁𝑓𝑓_𝑠𝑠𝑠𝑠𝑛𝑛 ) + 2 ∙ 𝑃𝑃𝑃𝑃1_𝑁𝑁𝑖𝑖𝑁𝑁𝑓𝑓_𝑃𝑃𝑃𝑃1_𝑠𝑠𝑠𝑠𝑛𝑛 =  𝑃𝑃𝑃𝑃1_𝑠𝑠𝑠𝑠𝑛𝑛_𝑑𝑑𝑓𝑓𝑑𝑑 = 𝑇𝑇1 
𝑃𝑃𝑃𝑃1_𝑃𝑃𝑃𝑃𝑃𝑃1 + 𝑃𝑃𝑃𝑃𝑃𝑃1_𝑠𝑠𝑠𝑠𝑛𝑛 =  𝑃𝑃𝑃𝑃𝑃𝑃1_𝑠𝑠𝑠𝑠𝑛𝑛_𝑑𝑑𝑓𝑓𝑑𝑑 = 𝑇𝑇2 
 
where  












Here 𝐶𝐶ℎ𝑖𝑖_𝑃𝑃𝑃𝑃1_𝑛𝑛𝑖𝑖𝑁𝑁𝑓𝑓 is the antibody cross-arm binding efficiency, and 𝑔𝑔𝑑𝑑𝑚𝑚𝑚𝑚𝑑𝑑_𝑇𝑇_𝑛𝑛𝑖𝑖𝑁𝑁𝑓𝑓 is the 
volume fraction available to nivolumab. 
Let PD-L1 – PD-1 = X and x = X/T2. We rewrite the equation as: 














� 𝑑𝑑 − 𝑇𝑇1
𝑇𝑇2
= 0    (Eq. 12)  
 
In our model, Eq. 12 is solved respect to x using Newton–Raphson method with initial guessing 
point 𝑑𝑑0 = 0. Then the total number of PD-L1 – PD-1 bonds, which equals to xT2, during 
immune synapse is calculated dynamically during simulation when each CD8+ T cell interacts 
with cancer cells. It can be shown that for the parameters of the problem the roots of the equation 
are real, and we choose the root in the interval 0<x<1. 
CD8+ T cell recruitment, expansion, and death 





= 𝑞𝑞𝑇𝑇𝐴𝐴,𝑡𝑡𝑡𝑡𝑑𝑑𝑡𝑡𝑡𝑡 𝑖𝑖𝑖𝑖 ∙ 𝑉𝑉𝑇𝑇 ∙ 𝑇𝑇𝐴𝐴,𝑐𝑐𝑐𝑐𝑛𝑛𝑑𝑑𝑟𝑟𝑑𝑑𝑙𝑙  (Eq. 13) 
where TA is the number of CD8+ effector T cells with TCR aligned with antigen A being 
recruited into the tumor at each time step, 𝑉𝑉𝑇𝑇 is the tumor volume, TA, central is the number of 
CD8+ effector T cell with TCR aligned with antigen A in the central compartment, and qTA,tumor in 
is the rate of CD8+ effector T cell with TCR aligned with antigen A transport into the tumor 
compartment. Therefore, in the ABM module, the probability of recruiting CD8+ T cell is 
defined as:  
𝑝𝑝𝑇𝑇𝐴𝐴,𝑟𝑟𝑐𝑐𝑐𝑐𝑟𝑟𝑟𝑟𝑖𝑖𝑑𝑑𝑐𝑐𝑑𝑑 = 𝑇𝑇𝐴𝐴,   𝑐𝑐𝑐𝑐𝑛𝑛𝑑𝑑𝑟𝑟𝑑𝑑𝑙𝑙 𝑘𝑘𝑟𝑟𝑐𝑐𝑐𝑐,𝑐𝑐𝑒𝑒𝑒𝑒𝑐𝑐𝑐𝑐𝑑𝑑𝑁𝑁𝑟𝑟    (Eq. 14) 
𝑘𝑘𝑟𝑟𝑐𝑐𝑐𝑐,𝑐𝑐𝑒𝑒𝑒𝑒𝑐𝑐𝑐𝑐𝑑𝑑𝑁𝑁𝑟𝑟 =  
𝑞𝑞𝑇𝑇𝐴𝐴,𝑡𝑡𝑡𝑡𝑑𝑑𝑡𝑡𝑡𝑡 𝑖𝑖𝑖𝑖 ∙ 𝛥𝛥𝑑𝑑 ∙ 𝑠𝑠𝑖𝑖𝑑𝑑𝑇𝑇_𝑝𝑝𝑇𝑇𝑟𝑟_𝑝𝑝𝑓𝑓𝑟𝑟𝑑𝑑
𝑤𝑤 ∙  𝜌𝜌𝑑𝑑𝑑𝑑ℎ𝑐𝑐𝑠𝑠𝑖𝑖𝑁𝑁𝑛𝑛
      
Here, 𝛥𝛥𝑑𝑑 is the time per time step, site_per_port is number of adhesion sites per port voxel, w is 
the weight of the QSP model contribution to the spQSP model, and ρadhesion is the total adhesion 
site density on tumor vasculature. 
In ABM module CD8+ T cell expands upon its activation by the adjacent cancer cell. Each 
CD8+ T cell divides every 𝑑𝑑𝑇𝑇_𝐶𝐶𝑃𝑃8 hours deterministically. Each CD8+ T cell is limited to 
𝑛𝑛𝑇𝑇_𝐶𝐶𝑃𝑃8 divisions before becoming senescent. The lifetime of CD8+ cell is normally distributed 
with mean µ𝑇𝑇_𝐶𝐶𝑃𝑃8  and standard deviation 𝜎𝜎𝑇𝑇_𝐶𝐶𝑃𝑃8 . All parameters are provided in the supplement. 
CD8+ T cell killing of cancer cells 
In the QSP module, the CD8+ T cell killing rate is defined as: 
𝑑𝑑𝐶𝐶
𝑑𝑑𝑑𝑑
= − 𝑘𝑘_𝐶𝐶_𝑑𝑑𝑇𝑇𝑑𝑑𝑑𝑑ℎ_𝑏𝑏𝑠𝑠_𝑇𝑇 ∙ 𝑇𝑇𝐶𝐶𝐶𝐶8
𝐶𝐶 +𝑇𝑇𝑐𝑐𝑐𝑐𝑙𝑙𝑙𝑙+𝑐𝑐𝑐𝑐𝑙𝑙𝑙𝑙




To translate that equation to the ABM module, the probability of a cancer cell killing by adjacent 
CD8+ T cell is calculated as: 
𝑝𝑝𝑘𝑘𝑖𝑖𝑙𝑙𝑙𝑙 =   1 − 𝑇𝑇−𝛥𝛥𝑑𝑑∙ 𝛼𝛼𝑐𝑐,𝐶𝐶𝐶𝐶8 
where 𝛥𝛥𝑑𝑑 is the length of each time step, and 𝛼𝛼𝑐𝑐,𝐶𝐶𝑃𝑃8 is defined as:  
𝛼𝛼𝑐𝑐,𝐶𝐶𝑃𝑃8 = 𝑘𝑘_𝐶𝐶_𝑑𝑑𝑇𝑇𝑑𝑑𝑑𝑑ℎ_𝑏𝑏𝑠𝑠_𝑇𝑇 ∙
𝑁𝑁𝐶𝐶𝑃𝑃8





 is the fraction of cytotoxic T cells among all cells in the Moore neighborhood of 
the target cancer cell.   
CD8+ T cell exhaustion 
CD8+ T cell can be exhausted by two distinct mechanisms in both QSP and ABM module. 
Exhaustion by PD1 - PD-L1 interaction: 
In the QSP module, the rate of CD8+ T cell being exhausted by PD1 - PD-L1 interaction is: 
𝑑𝑑𝑇𝑇𝐶𝐶𝑃𝑃8
𝑑𝑑𝑑𝑑
= − 𝑇𝑇𝐶𝐶𝑃𝑃8 ∗  𝑘𝑘𝑇𝑇𝐶𝐶𝐶𝐶8_𝑏𝑏𝑏𝑏_𝐶𝐶 ∙   
𝐶𝐶
𝐶𝐶 + 𝑇𝑇𝑇𝑇𝑇𝑇𝑙𝑙𝑙𝑙 + 𝑇𝑇𝑇𝑇𝑙𝑙𝑙𝑙
∙ 𝐻𝐻𝑃𝑃𝑃𝑃1(𝑋𝑋, 1)     (Eq. 16) 
where 𝑇𝑇𝑇𝑇𝑙𝑙𝑙𝑙 is the counts of cells other than T cell or cancer cell, and 𝐶𝐶
𝐶𝐶 +𝑇𝑇𝑇𝑇𝑇𝑇𝑙𝑙𝑙𝑙+𝑇𝑇𝑇𝑇𝑙𝑙𝑙𝑙
 is the fraction of 
cancer cells in the tumor. In the ABM module the probability of single CD8+ T cell being 
exhausted by PD1 - PD-L1 interaction is: 
 
𝑝𝑝𝑐𝑐𝑑𝑑ℎ𝑑𝑑𝑟𝑟𝑠𝑠𝑑𝑑,𝑃𝑃𝑃𝑃𝐷𝐷1 = 1 − 𝑇𝑇−∆𝑑𝑑 ∙ 𝑘𝑘_𝑇𝑇𝑐𝑐𝑒𝑒𝑒𝑒_𝑑𝑑𝑐𝑐𝑑𝑑𝑑𝑑ℎ_𝑏𝑏𝑏𝑏_𝐶𝐶 ∙ 𝐻𝐻𝑃𝑃𝐶𝐶1(𝑋𝑋,1))∗𝑞𝑞_𝑐𝑐  = 1 − 𝐵𝐵𝑃𝑃𝑃𝑃𝐷𝐷1𝐻𝐻𝑃𝑃𝐶𝐶1
(𝑋𝑋,1)𝑞𝑞_𝑐𝑐    (Eq. 17) 
 
here, 𝐵𝐵𝑃𝑃𝑃𝑃𝐷𝐷1 = 𝑇𝑇−∆𝑑𝑑 ∙ 𝑘𝑘_𝑇𝑇𝑐𝑐𝑒𝑒𝑒𝑒_𝑑𝑑𝑐𝑐𝑑𝑑𝑑𝑑ℎ_𝑏𝑏𝑏𝑏_𝐶𝐶 , and q_c is the fraction of cancer cells among all cells in 
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the Moore neighborhood of the target CD8+ T cell. Since we assume all cancer cells express PD-
L1 in the ABM module, q_c equals to 1. 
 
Exhaustion by Treg: 
In the QSP module, the rate of CD8+ T cell being exhausted by Treg is: 
                                   𝑑𝑑𝑇𝑇𝐶𝐶𝐶𝐶8
𝑑𝑑𝑑𝑑
= − 𝑇𝑇𝐶𝐶𝑃𝑃8 ∗ 𝑘𝑘𝑇𝑇𝐶𝐶𝐶𝐶8_𝑏𝑏𝑏𝑏_𝑇𝑇𝑟𝑟𝑐𝑐𝑇𝑇 ∙
𝑇𝑇𝑟𝑟𝑐𝑐𝑇𝑇
𝐶𝐶 +𝑇𝑇𝑐𝑐𝑐𝑐𝑙𝑙𝑙𝑙+𝑐𝑐𝑐𝑐𝑙𝑙𝑙𝑙
∗ (1 + 𝐻𝐻𝑃𝑃𝑃𝑃1)     (Eq. 18) 
In the ABM module the probability of single CD8+ T cell being exhausted by Treg is: 
𝑝𝑝𝑐𝑐𝑑𝑑ℎ𝑑𝑑𝑟𝑟𝑠𝑠𝑑𝑑,𝑇𝑇𝑟𝑟𝑐𝑐𝑇𝑇 = 1 − 𝑇𝑇−𝛥𝛥𝑑𝑑∗𝑘𝑘𝑇𝑇_𝐶𝐶𝐶𝐶8_𝑏𝑏𝑏𝑏_𝑇𝑇𝑡𝑡𝑡𝑡𝑇𝑇∗(1+𝐻𝐻𝑃𝑃𝐶𝐶1)∗𝑞𝑞_𝑑𝑑𝑟𝑟𝑐𝑐𝑇𝑇     (Eq. 19) 
Here q_treg is the fraction of Tregs in the Moore neighborhood of targeted CD8+ T cell.  
 
Treg recruitment, expansion and death 
In the QSP module, the recruitment rate is defined as: 
𝑑𝑑𝑇𝑇𝑟𝑟𝑐𝑐𝑇𝑇
𝑑𝑑𝑑𝑑
= 𝑞𝑞𝑇𝑇𝑟𝑟𝑐𝑐𝑇𝑇,𝑇𝑇,𝑖𝑖𝑛𝑛𝑉𝑉𝑇𝑇𝑇𝑇𝑟𝑟𝑐𝑐𝑇𝑇,𝐶𝐶 �1 −
𝑇𝑇𝑟𝑟𝑐𝑐𝑇𝑇
𝑇𝑇𝑟𝑟𝑐𝑐𝑇𝑇,𝑑𝑑𝑑𝑑𝑑𝑑𝑉𝑉𝑇𝑇
�     (Eq. 20) 
where 𝑞𝑞𝑇𝑇𝑟𝑟𝑐𝑐𝑇𝑇,𝑇𝑇,𝑖𝑖𝑛𝑛 is the rate of Treg transport into the tumor compartment, and 𝑇𝑇𝑟𝑟𝑐𝑐𝑇𝑇,𝑑𝑑𝑑𝑑𝑑𝑑 is the 
maximum number of Treg cells in the tumor compartment.  
 
The expansion of Treg is defined as: 
𝑑𝑑𝑇𝑇𝑟𝑟𝑐𝑐𝑇𝑇
𝑑𝑑𝑑𝑑






= 𝑅𝑅𝑇𝑇𝑟𝑟𝑐𝑐𝑇𝑇,𝑐𝑐𝑑𝑑𝑝𝑝      (Eq. 21) 
where 𝑘𝑘𝑇𝑇𝑟𝑟𝑐𝑐𝑇𝑇,𝑐𝑐𝑑𝑑𝑝𝑝 is the rate of Treg expansion induced by Arg-I, 𝐸𝐸𝐶𝐶50𝐴𝐴𝑟𝑟𝑇𝑇𝐴𝐴,𝑇𝑇𝑟𝑟𝑐𝑐𝑇𝑇 is half-maximal 




Since the tumor volume is not clearly defined in the ABM module (only one or several ROIs are 
considered), we substitute  𝑉𝑉𝑇𝑇 �1 −
𝑇𝑇𝑡𝑡𝑡𝑡𝑇𝑇
𝑇𝑇𝑡𝑡𝑡𝑡𝑇𝑇,𝑑𝑑𝑑𝑑𝑑𝑑𝑉𝑉𝑇𝑇
� with  𝑠𝑠𝑖𝑖𝑑𝑑𝑐𝑐_𝑝𝑝𝑐𝑐𝑟𝑟_𝑝𝑝𝑁𝑁𝑟𝑟𝑑𝑑
𝑤𝑤 ∙ 𝜌𝜌𝑑𝑑𝑑𝑑ℎ𝑡𝑡𝑒𝑒𝑖𝑖𝑡𝑡𝑖𝑖
. The recruitment mechanism is 
similar to CD8+ T cell recruitment  
𝑝𝑝𝑇𝑇𝑟𝑟𝑐𝑐𝑇𝑇,𝑟𝑟𝑐𝑐𝑐𝑐𝑟𝑟𝑟𝑟𝑖𝑖𝑑𝑑𝑐𝑐𝑑𝑑 =  𝑇𝑇𝑟𝑟𝑐𝑐𝑇𝑇,𝑐𝑐𝑐𝑐𝑛𝑛𝑑𝑑𝑟𝑟𝑑𝑑𝑙𝑙
𝑞𝑞𝑇𝑇𝑡𝑡𝑡𝑡𝑇𝑇,𝑡𝑡𝑡𝑡𝑑𝑑𝑡𝑡𝑡𝑡 𝑖𝑖𝑖𝑖 ∙ 𝛥𝛥𝑑𝑑 ∙ 𝑠𝑠𝑖𝑖𝑑𝑑𝑇𝑇_𝑝𝑝𝑇𝑇𝑟𝑟_𝑝𝑝𝑓𝑓𝑟𝑟𝑑𝑑
𝑤𝑤 ∙  𝜌𝜌𝑑𝑑𝑑𝑑ℎ𝑐𝑐𝑠𝑠𝑖𝑖𝑁𝑁𝑛𝑛
     (Eq. 22)  
 
Treg, central is the number of Treg in the central compartment, and qTreg,tumor,in is the rate of Treg 
transport into the tumor compartment. Additionally, in the ABM module, the time for expansion 
is inversely proportional to 𝑅𝑅𝑇𝑇𝑡𝑡𝑡𝑡𝑇𝑇,𝑡𝑡𝑑𝑑𝑒𝑒𝛥𝛥𝑑𝑑
𝑇𝑇𝑡𝑡𝑡𝑡𝑇𝑇
. The lifetime of Treg cell is normally distributed with 
mean µ𝑇𝑇𝑟𝑟𝑐𝑐𝑇𝑇  and standard deviation 𝜎𝜎𝑇𝑇𝑟𝑟𝑐𝑐𝑇𝑇 . All parameters are provided in the supplement. 
MDSC recruitment and death 
In the QSP module, MDSCs can be recruited in two ways: baseline recruitment and CCL2 
induced recruitment. The baseline recruitment is defined as: 
𝑑𝑑𝑑𝑑𝑃𝑃𝑆𝑆𝐶𝐶
𝑑𝑑𝑑𝑑
= 𝑘𝑘𝑀𝑀𝑃𝑃𝑀𝑀𝐶𝐶,𝑏𝑏𝑟𝑟𝑐𝑐𝑐𝑐(𝑑𝑑𝑃𝑃𝑆𝑆𝐶𝐶𝑑𝑑𝑑𝑑𝑑𝑑𝑉𝑉𝑇𝑇 − 𝑑𝑑𝑃𝑃𝑆𝑆𝐶𝐶)     (Eq. 23)  
 






     (Eq. 24)  
 
where 𝑘𝑘𝑀𝑀𝑃𝑃𝑀𝑀𝐶𝐶,𝑏𝑏𝑟𝑟𝑐𝑐𝑐𝑐 is the baseline of MDSC migration rate into tumor, 𝑘𝑘𝑀𝑀𝑃𝑃𝑀𝑀𝐶𝐶,𝑟𝑟𝑐𝑐𝑐𝑐 is the normal rate 
of MDSC recruitment into tumor, 𝑑𝑑𝑃𝑃𝑆𝑆𝐶𝐶𝑑𝑑𝑑𝑑𝑑𝑑𝑉𝑉𝑇𝑇 is the maximum number of MDSC in tumor 




To translate such mechanism into the ABM module, the baseline probability of recruiting a 






𝑤𝑤 ∙  𝜌𝜌𝑑𝑑𝑑𝑑ℎ𝑇𝑇𝑠𝑠𝑖𝑖𝑓𝑓𝑛𝑛
     (Eq. 25)  
 and probability of recruiting a MDSC induced by CCL2 is: 
𝑝𝑝𝑀𝑀𝑃𝑃𝑀𝑀𝐶𝐶 ,𝑟𝑟𝑐𝑐𝑐𝑐 = 𝑘𝑘𝑀𝑀𝑃𝑃𝑀𝑀𝐶𝐶,𝑟𝑟𝑐𝑐𝑐𝑐
(𝑑𝑑𝑃𝑃𝑆𝑆𝐶𝐶𝑑𝑑𝑑𝑑𝑑𝑑𝑉𝑉𝑇𝑇 − 𝑑𝑑𝑃𝑃𝑆𝑆𝐶𝐶)
𝑉𝑉𝑇𝑇
∙ 𝛥𝛥𝑑𝑑 ∙ site_per_port
w ∙  ρadhesion
∙ 𝐶𝐶𝐶𝐶𝑃𝑃2
𝐸𝐸𝐶𝐶50𝐶𝐶𝐶𝐶𝐷𝐷2,𝑟𝑟𝑐𝑐𝑐𝑐 + 𝐶𝐶𝐶𝐶𝑃𝑃2
     (Eq. 26)  
 
The death rate of MDSC in the QSP module is: 
𝑑𝑑𝑑𝑑𝑃𝑃𝑆𝑆𝐶𝐶
𝑑𝑑𝑑𝑑
= −𝑘𝑘𝑀𝑀𝑃𝑃𝑀𝑀𝐶𝐶,𝑑𝑑𝑐𝑐𝑑𝑑𝑑𝑑ℎ𝑑𝑑𝑃𝑃𝑆𝑆𝐶𝐶        (Eq. 27)  
where 𝑘𝑘𝑀𝑀𝑃𝑃𝑀𝑀𝐶𝐶,𝑑𝑑𝑐𝑐𝑑𝑑𝑑𝑑ℎ is the death rate of MDSC, so in the ABM module, the dying probability of a 
MDSC is:  
𝑝𝑝𝑀𝑀𝑃𝑃𝑀𝑀𝐶𝐶,𝑑𝑑𝑐𝑐𝑑𝑑𝑑𝑑ℎ = 1 − 𝑇𝑇−𝑘𝑘𝑀𝑀𝐶𝐶𝑀𝑀𝐶𝐶,𝑑𝑑𝑡𝑡𝑑𝑑𝑡𝑡ℎ×𝛥𝛥𝑑𝑑     (Eq. 28)  
 
 
2.1.5 Integrating QSP and ABM sub-models 
The spQSP model simulates dynamic response of four compartments identical to the QSP model, 
and the ABM module is constructed specifically to represent a spatially-resolved volume in the 
tumor compartment. A subset (set A) of the species, including cancer cells, CD8+ T cells, Tregs 
and MDSC, are partially built into the ABM module. We simulate all remaining species in both 
tumor compartment and other compartments (set Ac) with the ODE system from the QSP model. 
For the species from set A of the tumor compartment, a portion wQSP is simulated by the QSP 
module, and the remaining 1- wQSP is represented by the ABM module. Also, information 
exchange between set A and set Ac species is reflected in the ABM module (Supplemental 
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Figure 7). For instance, recruiting CD8+ T cells, Treg and MDSCs from the central compartment 
to the QSP tumor compartment is scaled by wQSP, and central compartment immune cell 
abundance is subtracted by recruited immune cell in the ABM tumor compartment. Here, the 
nivolumab concentration in the tumor compartment of the QSP module equals nivolumab 
concentration in the ABM module. The dead cancer cells in the ABM are tracked so that the 
number can be added to the tumor-specific antigen species in the QSP module after being 
multiplied by a scaling factor. We then calculate peptide-MHC abundance on antigen presenting 
cells (APCs) in the lymph node compartment, which initiates CD8+ T cell priming process. 
 
 
Figure 2: A) Graphical illustration of spQSP model’s workflow. Set 𝐴𝐴𝑄𝑄𝑀𝑀𝑃𝑃 are the compartments and species 
modeled in both QSP and ABM module. Set 𝐴𝐴𝐶𝐶 are the compartments and species only modeled in the QSP module. 
B) Workflow of synchronizing QSP with ABM module at each time step during the simulation. 
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Our spQSP platform can include multiple ROIs simultaneously in the ABM module to simulate 
spatio-temporal dynamics of the tumor microenvironment. Only one ROI is included in this 







     (Eq. 29)  
where CQSP and CABM are the number of cancer cells in the QSP module and ABM module, 
respectively. We calculate the number of recruited immune cells and the amount of tumor 
neoantigen produced in the ABM. These quantities are then multiplied by the scaling factor s and 
updated in the QSP module.  
 
Since the QSP and ABM modules are simulated separately, for each timestep ∆𝑑𝑑, the ABM 
module is calculated first, with values of the QSP module from the previous timepoint (t = τ). 
Then the solution of QSP module at time t = τ + ∆𝑑𝑑   is computed. Next, recruited immune cells 
and generated tumor neoantigens by the ABM module are updated to the QSP module, and both 
QSP and ABM modules are synchronized at time t = τ +∆𝑑𝑑.   
2.1.6 Transport of soluble factors in ABM 
The ABM module has two types of agents: cellular agents and molecular agents. All cellular 
agents were introduced in the previous section. Molecular agents are cytokines that are produced 
by cells in the ROI, including INF-𝛾𝛾, IL-2, and CCL2, and molecules NO and Arg-I. The partial 
differential equation (PDE) governing the concentration of each soluble factor c is defined as: 
𝜕𝜕𝑇𝑇
𝜕𝜕𝑑𝑑
= 𝑃𝑃𝛻𝛻2𝑇𝑇 − 𝜇𝜇𝑇𝑇 + 𝑆𝑆(𝑑𝑑,𝑠𝑠, 𝑧𝑧, 𝑑𝑑)    (Eq. 30)  
 
where D is molecular diffusivity, μ is the degradation rate, and S is the secretion rate of c in 
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voxel (x, y, z) at time t, and it becomes 0 when there is no source for c.  
 
We use finite volume method implemented in the BioFVM software to solve PDE equations 
(Ghaffarizadeh et al., 2016). Spatial discretization of the molecular layer matches the voxels in 
the agent layer. All six surfaces of the simulated parallelepiped (or cubic) volume follow no-flux 
boundary conditions. When a soluble factor is released by a cell, a source of the factor is created 
at the location corresponding to the center of the cell’s voxel. When the cell migrates to other 
voxels in the volume, the source moves along with the cell agent to the center of the target voxel. 
2.2 Genomic Data Availability and Neoantigen Identification 
To identify tumor neoantigens and their expression in each cancer cell, we downloaded 
TNBC single cell RNA-seq data and WES from Chung et al.(Chung et al., 2017), available in the 
NCBI Gene Expression Omnibus database under the accession code GSE75688. Briefly, the 
WES data were used to define neoantigens following the steps outlined below. Then the single-
cell RNA-seq data from the tumor cells were used to quantify the heterogeneity of expression of 
identified neoantigens. The schematic workflow of neoantigen identification is presented in 
Figure 3. All genes identified as neoantigen genes from this pipeline were filtered for inclusion 
in TSNAdb, a database that stores all immunogenic mutations from The Cancer Genome Atlas 
(TCGA) and the immune response was confirmed by Immune Epitope Database (IEDB) (Wu et 
al., 2018). This analysis yields patient-specific estimates of neoantigen expression, able to model 




Figure 3: Workflow of immunogenic neoantigen identification from single cell RNA-seq of TNBC in Chung et al, 
including data source, MHC-peptide binding prediction, immunogenicity prediction, neoantigen expression on 
cancer cell, integration with spQSP model. 
 
2.3 MHC (HLA) Selection 
As most immunotherapies restore cytotoxic activity of CD8+ T lymphocytes, our QSP 
model focuses on the effect of CD8+ T cells. Therefore, we primarily focus on MHC-I binding 
with epitopes. The raw sequencing data for the WES data were not available, challenging direct 
MHC estimation. Therefore, to best ensure MHC-I alleles that we selected are expressed across 
the population, we chose 16 MHC-I alleles that are expressed in more than 5% of the overall 
population (Table 3) from 1000 Genome HLA frequency Data (Gourraud et al., 2014). Since 
Chung et al. study was conducted in Korea, we only rank the frequency within Asian population 
assuming majority patients in the study were Asian. 
HLA Locus  
  East Asian (n = 371 * 2)  
Allele  Chinese from Beijing, China (n = 90 * 2)  
Chinese from Denver-
Colorado, USA (n = 90 * 2)  
Chinese from South 
China (n = 100 * 2)  
Japanese from Tokyo (n 
= 91 * 2)  
A*0201g  30 (16.67%)  15 (8.33%)  20 (10%)  19 (10.44%)  
A*0206g  8 (4.44%)  10 (5.56%)  9 (4.5%)  17 (9.34%)  
A*0207g  4 (2.22%)  17 (9.44%)  30 (15%)  2 (1.1%)  
A*1101g  45 (25%)  52 (28.89%)  52 (26%)  13 (7.14%)  
A*2402g  32 (17.78%)  31 (17.22%)  38 (19%)  68 (37.36%)  
A*3303g  15 (8.33%)  4 (2.22%)  12 (6%)  19 (10.44%)  
B*1301  7 (3.89%)  14 (7.78%)  15 (7.5%)  2 (1.1%)  
B*4001g  22 (12.22%)  28 (15.56%)  41 (20.5%)  9 (4.95%)  
B*4601g  21 (11.67%)  19 (10.56%)  37 (18.5%)  10 (5.49%)  
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B*5101g  12 (6.67%)  11 (6.11%)  10 (5%)  14 (7.69%)  
C*0102g  29 (16.11%)  32 (17.78%)  40 (20%)  24 (13.19%)  
C*0303g  11 (6.11%)  8 (4.44%)  16 (8%)  25 (13.74%)  
C*0304  14 (7.78%)  23 (12.78%)  34 (17%)  25 (13.74%)  
C*0602  14 (7.78%)  13 (7.22%)  7 (3.5%)  3 (1.65%)  
C*0702g  30 (16.67%)  37 (20.56%)  46 (23%)  26 (14.29%)  
C*0801g  19 (10.56%)  19 (10.56%)  15 (7.5%)  14 (7.69%)  
Table 3: Selected Human Leukocyte Antigen (HLA) for neoantigen peptide binding prediction from Gourraud et 
al. Each selected HLA allele must be expressed in more than 5% of the overall Asian population. In total, 16 alleles 
were chosen based on the criteria. 
2.4 MHC-I Binding Prediction 
Chung et al. WES data contain only single nucleotide polymorphism (SNP), so indels and 
frameshifts were excluded from forming neoantigens(Chung et al., 2017). We used netMHCpan 
4.0, a web tool predicting peptide-MHC affinity based on neural network approach to select 
MHC-epitopes (Jurtz et al., 2017). The inputs are 16 HLA alleles selected from previous step and 
21-mer-peptide with the mutational site at the center, and the output is the MHC-epitope 
complex predicted by netMHCpan 4.0. 
2.5 MHC-epitope Immunogenicity Prediction 
To ensure predicted MHC-epitopes complexes are immunogenic, we used IEDB Class I 
Immunogenicity web tool to predict if MHC-epitopes complexes can elicit immune responses 
(Calis et al., 2013). Calis et al. uses “immunogenicity score” to quantify strength of immune 
response elicited by epitopes. Based on experimental data, immunogenic epitopes have average 
immunogenicity score 0.097 verses non-immunogenic epitopes score 0.01. Therefore, epitopes 
with immunogenicity score higher than 0.1 are considered immunogenic, and the genes that 
express the peptide are identified as tumor neoantigens.  
2.6 Tumor Neoantigen Expression in Cancer cell and T cell in ABM module 
  We further use the single-cell RNA-seq data from Chung et al. to model neoantigen 
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heterogeneity within the tumor cells(Chung et al., 2017). We apply SAVER to the single cell 
expression profiles to estimate expression profiles in spite of the missing data from the technical 
dropout in single cell RNA-seq and log transform estimated transcript per million (TPM) 
values(M. Huang et al., 2018). We use kernel density estimation to approximate the expression 
distribution of one antigen across all cancer cells within single patient, excluding cells with 
expression values in the bottom 10% in this estimate to account for dropout. This binary 
expression value is used as input to the spQSP model, using this simplification of binary tumor 
neoantigen expression (expressed vs. not expressed) in each cancer cell as input to the model. 
We use these data to calculate the coefficient of variance (CoV) of neoantigen frequency to 
quantify tumor neoantigen heterogeneity, expressed as  
𝜎𝜎𝑑𝑑𝑖𝑖𝑡𝑡𝑖𝑖𝑇𝑇𝑡𝑡𝑖𝑖/𝑐𝑐𝑡𝑡𝑡𝑡𝑡𝑡
𝜇𝜇𝑑𝑑𝑖𝑖𝑡𝑡𝑖𝑖𝑇𝑇𝑡𝑡𝑖𝑖/𝑐𝑐𝑡𝑡𝑡𝑡𝑡𝑡
, where 𝜎𝜎𝑑𝑑𝑛𝑛𝑑𝑑𝑖𝑖𝑇𝑇𝑐𝑐𝑛𝑛/𝑐𝑐𝑐𝑐𝑙𝑙𝑙𝑙 is the 
standard deviation of neoantigen frequency, and 𝜇𝜇𝑑𝑑𝑛𝑛𝑑𝑑𝑖𝑖𝑇𝑇𝑐𝑐𝑛𝑛/𝑐𝑐𝑐𝑐𝑙𝑙𝑙𝑙 is the mean of neoantigen 
frequency. This metric enables us to represent the difference between diverse neoantigen 
expression within a small subpopulation of tumor cells from uniform neoantigen expression 
across distinct subclones of cancer cells within the tumor.  
The T cell recognition is modified from our previously published model of  TNBC(Wang 
et al., 2020) to pair specific TCRs to neoantigens. We leveraged this new model of T cell 
recognition to study the impact of tumor cell heterogeneity on patient-specific immunotherapy 
response.  The spQSP model further requires that T cells can recognize each antigen to yield 
effective T cell killing. Specifically, alignment between the hypervariable loop (CDR3α, 
CDR3β) and epitopes is required for immune response and killing of cancer cell, thus it is crucial 
to describe TCR-epitope specificity in our mathematical model (Glanville et al., 2017; Singh et 
al., 2017). We assume that MHC-epitope (pMHC) and T cell receptor (TCR) on CD8+ T cell has 
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one-to-one relationship: each TCR can only recognize one and only one epitope, and the 
graphical illustration is shown in Figure 4. 
 
Figure 4: Illustration of TCR specificity in current model. To kill the cancer cell, TCR must match existing antigen 
of the target cancer cell. A) The TCR antigen alignment leads to cancer cell death. B) The TCR cannot align with 
any antigen in the cancer cell, hence the cancer cell survives. 
 
2.7 Simulated Digital Pathology Data 
 To resemble digital pathology data, the spatial result from ABM module is sliced every 
0.05 mm in the y direction; therefore, twenty immunofluorescence (IF) panels are generated at 
each time point. Our simulated IF panels are compared with the multiplexed data in Keren et al. 
We applied the same metric from Keren et al. -- mixing score, a method quantifying the 
separation between the immune cells and cancer cells. The mixing score is calculated based on 
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fraction of immune cells adjacent to cancer cells. We define cell A is in contact with the target 
cell if cell A is in the 2D von Neumann neighborhoods (range = 1 pixel)of the target cell (Das, 
2011). All patient TME are distinguished between two categories: mixed (mixing score > 0.22) 
and compartmentalized (mixing score < 0.22). 
2.8 Model Initialization and Simulation 
Since the number of cancer cells sampled in the scRNA-seq data was low (13 to 28 cancer cells 
per sample), we use bootstrapping to increase number of cancer cells to 1000 as the initial 
condition for all simulations. To represent inter-patient variability, a virtual patient cohort is 
generated by varying a subset of model parameters. Those values are sampled using Latin 
Hypercube Sampling (LHS) based on estimated distributions. A set of complete model 
parameters is defined as a virtual patient, and each virtual patient cohort contains one hundred 
patients in this study. All model parameters are provided in the Supplemental Material. In the 
model, anti-PD-1 immune checkpoint inhibitor nivolumab at 3mg/kg is administered to every 
virtual patient via bolus injection every two weeks, and each simulation last for 200 days. The 
spQSP model is built with C++ language, and all simulations are run on a Linux compute cluster. 
2.9 Sensitivity Analysis 
To thoroughly investigate the impact of input parameter on tumor progression, including cancer 
cell counts, immune cell density, and other features, we conduct parameter sensitivity analysis 
for 18 parameters. The values of analyzed parameters are sampled using Latin Hypercube 
Sampling (LHS)(Helton & Davis, 2003). We sampled 400 parameter sets based on approximated 
distribution. Partial Rank Correlation Coefficient (PRCC) is calculated between treatment 





3.1 Tumor Neoantigen Abundance Impact on Tumor Progression 
We adapted our previous parameterization of the spQSP model for TNBC (Wang et al., 
2020) to model patient specific-responses to anti-PD-1 (nivolumab) monotherapy using 
combined WES data and scRNA-seq data of tumor cells from Chung et al. (Chung et al., 2017).  
This dataset contains 4 total TNBC patients from the 11 total patients sampled (patient 7, 8, 10, 
and 11, Figure 5) that reflect a range of antigen burdens (Patient 7: 15 neoantigens; Patient 8: 17 
neoantigens; Patient 10: 6 neoantigens, and Patient 11: 4 neoantigens in total) and CoV of 
neoantigen frequency reflective of intra-tumoral heterogeneity of neoantigen expression (Patient 
7: 0.140, Patient 8: 0.193, Patient 10: 0.396, Patient 11: 0.142). Therefore, incorporating this 
dataset into the tumor compartment of the spQSP model enables us to study how tumor 




Figure 5:  Neoantigen expression frequency (in TPM) for each patient using the single cell sequencing data (shown 
in blue histogram, Patient 7: 15 neoantigens, Patient 8: 17 neoantigens, Patient 10: 6 neoantigens, Patient 11: 4 
neoantigens). Kernel density estimation (shown in red line) is applied to approximate the expression distribution of 
each identified antigen across all cancer cells within single patient. Neoantigen with expression values in the bottom 






Figure 6: Cell frequency distribution of bootstrapped 1000 cancer cells in ABM at Day 0. X-axis represents number 
of neoantigens in single cancer cell; y-axis represents cell frequency contains n neoantigens. 
 
Treatments were simulated for 200 days, with tumor progression snapshots taken at Day 0, 
30, and end of treatment for all patient samples (Figure 7). Only patients 7 and 8 who had the 
highest neoantigen burden responded to the nivolumab therapy. Our results qualitatively agree 
with clinical data suggesting that immunotherapy is more effective in patients with more tumor 




Figure 7: Visualization of the ABM simulation result. Tumor growth is simulated for 200 days total (no treatment vs. 
nivolumab monotherapy). The dosing regimen for nivolumab is 3mg/kg every 2 weeks starting from day 0. 
Snapshots are taken at day 0, day 30, and end of simulation (≤ day 200). Light pink: Stem-like cancer cell; Brown: 
Progenitor cancer cell; Dark Brown: Senescent Cancer cell; Cyan: CD8+ effector T cell; Blue: CD8+ cytotoxic T 
cell; Purple: Exhausted CD8+ T cell; Red: FoxP3+ T cell; Yellow: MDSC.  
In clinical practice, TMB is used as a surrogate to tumor neoantigen as immunogenic 
neoantigens are more complicated to identify, and cancer genes with higher mutation rate can 
potentially produce more tumor neoantigens (Fancello et al., 2019). To further verify our 
findings, four virtual patient cohorts are generated based on each patient’s neoantigen profile 
(400 virtual patients in total). Then, we simulate tumor progressions for all four virtual patient 
cohorts receiving no treatment vs. nivolumab monotherapy with dosing regimen of 3mg/kg every 
2 weeks starting at Day 0 (Figure 8, 9). We define a patient as a “responder” if tumor count is 
below 1000 cancer cells by the end of the simulation. Among 400 virtual patients who received 
nivolumab monotherapy 31 (8 %) responded, which is qualitatively consistent with clinical 
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results(Planes-Laine et al., 2019). Simulated cancer cell counts were reduced significantly only 
in the two patients with highest neoantigen burden (Patient 7: 12.0% reduction, p-value of 
0.0011; Patient 8: 22.7% reduction, p-value of 8.1 × 10−7; Patient 10: 0.9% reduction, p-value 
of 0.99; Patient 11: 2.9% reduction, p-value of 0.72; Supplemental Figure S4). This further 
demonstrates that our model correctly models that patients with more tumor neoantigens 
potentially have better clinical outcome. 
 
 
Figure 8: Cancer cell progression (200 days) comparison between no treatment vs. nivolumab monotherapy (n = 
100) for each patient’s antigen profile, and the parameter ranges are derived from Wang et al. Solid line represents 







Figure 9: Spider plot of 400 randomly selected virtual patients under four different patient neoantigen profiles. 
 
 Next, we use these simulations to further analyze immune biomarkers associated with 
individual patients. We use simulated cell type abundances to investigate whether clinically 
established immune biomarkers also have predictive power in our model. All values are taken at 
day 30 of the simulation to mimic biopsy at early-stage treatments. The density of CD8+ T cells 
and myeloid-derived suppressor cells (MDSCs) have strong predictive power of differentiating 
responders and non-responders (Figure 10A, 10B). Somewhat counterintuitively, responders 
have higher tumor FoxP3+ density (Figure 10C), but this result is also consistent with clinical 
data(Yeong et al., 2017).  Furthermore, the ratio of CD8+ T to FoxP3+ T cells has been regarded 
as a positive biomarker of response to immunotherapy (Liu et al., 2011). In Figure 10D, our 
simulations show that CD8+/FoxP3 ratios for patients who responded to nivolumab had 2.14 
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times of the ratio for non-responders (p = 3.9 × 10−16). Altogether, integration of scRNA-seq 
data of tumor cells with the spQSP model qualitatively reproduced immune profiles that 
resemble clinical results and showed that tumor progression could be predicted by conventional 
biomarkers. 
 
Figure 10: Immune biomarker comparison between responders and non-responders at Day 30 of the treatment. A) 
CD8+ effector T cells; B) MDSCs; D) FoxP3+ regulatory T cells; D) CD8+ effector T cell and FoxP3+ regulatory 
T cell ratio. (Student t-test, ns: 5.00e-02 < p <= 1.00e+00; *: 1.00e-02 < p <= 5.00e-02; **: 1.00e-03 < p <= 
1.00e-02; ***: 1.00e-04 < p <= 1.00e-03; ****: p <= 1.00e-04) 
 
3.2 Tumor Neoantigen Heterogeneity Influence Treatment Outcome 
 Our simulations demonstrate that Patient 10 has the worse treatment outcome (1%) than 
Patient 11 (3%) despite the fact that Patient 10 has more tumor neoantigens than Patient 11 (6 
and 4, respectively). This observation seems contradictory to the results presented above and 
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utility of TMB as an immunotherapy biomarker. Given that Patient 10 has the highest CoV of 
tumor neoantigen, we hypothesize that patients with higher tumor neoantigen heterogeneity have 
worse prognosis due to a lower probability of T cell recognition of an individual antigen. We test 
this hypothesis by increases the number of T cell clones in the simulations of Patient 10 and 11 
to levels that enable these patients to respond to nivolumab therapy. As we did in the previous 
section, we sampled two additional virtual patient cohorts under both Patient 10’s and 11’s 
neoantigen profiles (200 virtual patients total) and simulate tumor progression under treatment 
from nivolumab monotherapy for patients from both cohorts. The results show that tumor in 
Patient 10 acquired immunotherapy resistance at a later timepoint of the treatment than in the 
original simulations for a lower number of T cells (Fig 11A), whereas tumor in Patient 11 is 
stably controlled (Figure 11B). On average, tumor in Patient 11 contains 25.7% fewer cancer 
cells than that in Patient 10 (p = 6.3 × 10−3, Student t-test) (Figure 11H).  
To further investigate how higher tumor neoantigen heterogeneity leads to 
immunotherapy resistance, we focused on the neoantigen composition of cancer cells in the 
tumor. We found that cancer cells with fewer tumor neoantigens tend to survive throughout the 
treatment because they are less likely to be killed by CD8+ cytotoxic T cells (Figure 11C - F). 
Since the cancer cells remaining after treatment as immunotherapy resistant contain fewer tumor 
neoantigens, T cell diversity also reduces over the course of the treatment (Figure 11G). To 
summarize, high tumor neoantigen heterogeneity leads to the reduction of abundance of 
activated CD8+ in the tumor which in turn causes the immunotherapy resistance. This process is 
better reflected in case of Patient 10. In contrast, since at least 3 neoantigens are expressed in 
cancer cells in Patient 11, the number of activated CD8+ T cell stays stable. Therefore, the 
efficacy of nivolumab is preserved. This is in agreement with clinical studies that demonstrated 
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that higher CD8+ T cell diversity demonstrate superior responses to immunotherapy in NSCLC 
and mesothelioma (Han et al., 2020; Vroman et al., 2020).  
 
Figure 11: A, B) 3-D visualization of ABM results for Patient 10 and Patient 11 by the end of the treatment, 
respectively. C, D) Visualization of cancer cells and immune cells for Patient 10 and Patient 11 by the end of the 
treatment, respectively. Cancer cells are colored by neoantigen clones (same legend for E and F). E, F) Cancer cell 
composition in the ABM module over the 200-day treatment for Patient 10 and 11, cancer cells are grouped by 
tumor neoantigen they contain. G) Time-dependent T cell receptor (TCR) entropy over the course of nivolumab 
treatment. H) Cancer cell progression for all virtual patients using patient 10’s and 11’s tumor neoantigen profiles 
under nivolumab over 200 days (n = 100). Solid line represents average cancer cell count, and shaded area 






We explore the simulated post-treatment cancer cell composition of both virtual patient 
cohorts to reinforce our findings (Figure 12). The average antigen expressed on cancer cell is 
significantly reduced for Patient 10 (pre-treatment: 4.02, post-treatment: 2.47, p = 1.45 × 10−12, 
Student t-test), whereas the result is not significant for Patient 11 (pre-treatment: 3.45, post-
treatment: 3.35, p = 0.49, Student t-test). Our simulations are consistent with Gejman et al. data 
that diverse neoantigens expression leads to failure of immune-mediated cancer cell 
elimination(Gejman et al., 2018). Clinical results for NSCLC patients also indicate that high 
neoantigen heterogeneity negatively impacts treatment outcomes(McGranahan et al., 2016). Our 
results indicate that tumor neoantigen heterogeneity, which is quantified as CoV, can be regarded 




Figure 12: Cancer cell composition at the end of the treatment. Left: 100 simulations for 200 days nivolumab 
treatment under Patient 10’s neoantigen profile.  Right: 100 simulations for 200 days nivolumab treatment under 
Patient 11’s neoantigen profile. Cancer cells are grouped by neoantigens they contain. 
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3.3 Results of simulations resemble spatial clinical data.  
 While the single cell RNA-sequencing data used to initialize our model is from 
dissociated cells, and advantage of the spQSP model is its ability to capture the spatial resolution 
of tumors. Comparing spatial molecular data from digital pathology data with the spatial 
distribution of cells from the spQSP simulations validate the model. Thus, we qualitatively 
compare the simulated cell distribution from the ABM module with Keren et al. multiplexed 
pathology proteomics imaging data from TNBC patients (Keren et al., 2018). The data use 
multiplexed ion beam imaging quantifying in situ 36 protein expression in 41 TNBC patients.  In 
that study, patients with compartmentalized TME quantified through a mixing ratio between 
tumor and immune cells exhibited better overall survival rates. To compare our simulations to 
the structure of response in Keren et al., we calculate tumor mixing score on the simulated spatial 
distribution of cells on Day 60 and observed consistent results: both Patient 10’s samples form 
mixed tumor (Sample 1 mean mixing score: 0.71, Sample 2 mean mixing score: 0.75, Figure 13 
top), and they are predicted to have worse treatment outcome (Das, 2011). In contrast, both 
samples from Patient 11 are compartmentalized TME (Sample 1 mean mixing score: 0.17, 
Sample 2 mean mixing score: 0.12, Figure 13 bottom). We hypothesize that in 
compartmentalized tumors cancer cells’ growth is impeded by the immune system. Even though 
the results from a small sample size with qualitative comparison to the distributions in this larger 
cohort, these simulations demonstrate that our spQSP model can simulate spatial distributions 






Figure 13: Samples of simulated immunofluorescence (IF) for patient 10 and 11 at Day 60. The mixing score is 
calculated based on the method from Keren et al (Patient 10: Sample 1 mean mixing score: 0.71, Sample 2 mean 
mixing score: 0.75, Patient 11: Sample 1 mean mixing score: 0.17, Sample 2 mean mixing score: 0.12). The cross-
section of IF is taken along the y-axis at 0.21 mm, 0.51mm, and 0.81 mm. Red: Stem-like cancer cell; Magenta: 
Progenitor cancer cell; Dark Purple: Senescent Cancer cell; Cyan: CD8+ effector T cell; Light Blue: CD8+ 




3.4 Sensitivity Analysis 
 To test the uncertainty of the spQSP model predictions, we performed global sensitivity 
analysis for 18 input parameters, including Cancer cell growth rate, T cell clone per antigen, PD-
L1(2) expression level, etc. Output parameters include counts of post-treatment cancer cells, 
CD8+ T cells, Treg, and MDSC in both QSP and ABM modules. We used Partial Rank 
Correlation Coefficient (PRCC) to quantify the uncertainty of input parameters (Figure 14). In 
general, the output values in the QSP module have very similar sensitivity as output values in the 
ABM module for the same input parameter. The results are consistent with the notion that the 
QSP and ABM modules are generally coupled. However, we saw discrepancies for some input 
parameters that will be discussed in the next section. We found that Cancer cell growth rate, T 
cell clone per antigen, T cell killing rate, PD-L1 expression level, and Maximum MDSCs have 




Figure 14: Global sensitivity analysis of 18 parameters sampled by Latin Hypercube Sampling (LHS) method. The 








4. Discussion and Conclusion 
In this study, we investigate how tumor neoantigen burden and heterogeneity impact the 
efficacy of immunotherapy by incorporating high-throughput sequencing data into a 
computational spatial spQSP model of immunotherapy response. To enable the integration of 
high-throughput data, our spatial spQSP model blends multiple mathematical modeling 
frameworks. First, the QSP module simulates tumor progression at organ and whole patient level 
with parameters that are specifically defined for TNBC. However, due to the limitation of the 
compartmental QSP model, spatial heterogeneity is not represented. The addition of the ABM 
module of the tumor and its microenvironment allows us to overcome this limitation. The 
discretized agents allow us to further differentiate phenotypic characteristics. The ABM module 
recapitulates the heterogeneity and spatio-temporal phenomena in a tumor. In our current spQSP 
platform, cancer cells have three distinctive states (stem-like, progenitor, and senescent) and 
express distinctive neoantigens based on available scRNA-seq data. In addition, CD8+ T-cells 
can be further categorized by their TCR. Therefore, the ABM module captures more realistic 
immune/tumor interaction by recapitulating T-cell specificity and enables direct integration of 
single cells from high-throughput data to initialize the model. Leveraging the available public 
domain data, we focused this study on the integration of single cell data from tumor cells. 
Simulations based on this patient-specific distribution of tumor cells confirm that high antigen 
expression as well as homogeneity in antigen expression are associated with immunotherapy 
response. Although the initial condition of the ABM module relied on non-spatially resolved 
scRNA-seq data, we can still compare our simulated data with available multiplexed spatial data 
qualitatively. Our results demonstrate the spQSP model reflects the spatial distribution of tumor 
microenvironments that are sensitive and resistant to immunotherapy, providing a foundation to 
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demonstrate that this model is a suitable platform for incorporating omics data with high spatio-
temporal resolution.  
The integration of a comprehensive spatial computational model and highly personalized 
data will facilitate designing optimal treatment regimens. However, we recognize that the current 
spQSP model has limitations. First, we observed that cancer cells grow slower between days 15 
and 30, which might not reflect the real biological processes. This indicates the QSP and ABM 
modules might require tighter coupling in subsequent versions of the model. The need for a 
stricter coupling between two modules is also reflected in the sensitivity analysis. The maximum 
Treg number in the tumor has a smaller impact on Treg abundance in the ABM module 
compared to QSP module (Figure 14). The tumor Treg recruitment in the QSP module is capped 
by the maximum Treg density in the tumor and the tumor volume. However, we removed the 
maximum capacity of Treg cells since the tumor volume is not clearly defined in the ABM 
module (as we only consider one or several region of interest (ROI) volumes and scale the results 
to the whole tumor). Secondly, some critical cell types, such as fibroblasts and macrophages are 
currently not explicitly accounted for in the model. Even though the immunosuppressive effect 
of macrophages is included implicitly in the QSP module, those cells need to be introduced 
explicitly in the future to represent a more comprehensive tumor immune landscape. Mi et al. 
have shown that the invasive front (IF) of TNBC tumors plays a significant role in forming 
tumor immune landscape, and the immune architecture is spatially heterogeneous especially 
between the IF and core regions of the tumor (Mi et al., 2020). Including normal tissue into our 
current spQSP platform will help tracking the dynamics of tumor IF and better defining tumor 
volume in the ABM module. Due to the COVID-19 pandemics, many clinical results were 
delayed. Therefore, we used public data as the sources of high throughput data without the 
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follow-up result. In the next project, the tumor progression prediction will be compared with the 
post-treatment outcome, which serves as the most convincing data to test the predicting power of 
our model. 
 The modeling of cellular agents of the tumor in the spQSP model provides the framework 
by which to integration scRNA-seq profiles into our spQSP model. As mentioned previously, 
these simulations have demonstrated the feasibility of leveraging high-throughput data to 
simulate a patient-specific tumor microenvironment. Here, we have incorporated tumor 
neoantigen expression from scRNA-seq into the spQSP model, and built extensive computational 
model using omics data. While this current study focused on tumor cells, future studies with 
comprehensive single cell characterization of both tumor and immune cells can be used to also 
initialize the immune cell composition in the computational model directly, expanding to the 
spatial organization for emerging spatial molecular platforms. Beyond cell types, single cell 
RNA-seq also captures additional biological features including cellular proliferation, cell state 
transitions, and signaling pathways not directly modeled in the agents in the tumor compartment 
of our spQSP model. To integrate newly discovered pathways, appropriate computational models 
are required to describe cell-to-cell interactions and protein expression dynamics. The 
conventional computational models include, but not limited to, mechanistic models (Bouhaddou 
et al., 2018; Zhao et al., 2019, 2021), statistical models (Avanzini & Antal, 2019; Szczurek et al., 
2020), and data-driven models (Aguilar et al., 2020).  
All model structures require certain extent of prior knowledge. Due to complexity and 
noise of the biological system, the prior knowledge obtained even from single cell data can be 
either insufficient or pretreatment data can fail to account for evolutionary processes in an 
individual tumor that are not modeled in our spQSP model. Those challenges lead to inaccurate 
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treatment outcome predictions for individual patients. A potential solution is using machine 
learning to train the optimal parameter sets on a defined mechanistic model (Yuan et al., 2021). 
In conclusion, spatially-resolved computational models driven by high-throughput data should 
provide insights into intra- and inter-tumoral heterogeneity and interactions between 
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